Danica 35

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Cyproterone acetate 2mg; Ethinylestradiol 0.035mg (micronised)

Disponible desde:

Viatris Limited

Designación común internacional (DCI):

Cyproterone acetate 2 mg

Dosis:

2mg/0.035mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Cyproterone acetate 2mg Ethinylestradiol 0.035mg (micronised) Excipient: Ethanol Lactose monohydrate Magnesium stearate Maize starch Opadry pink 03F540049 Povidone Purified talc Purified water  

tipo de receta:

Prescription

Fabricado por:

Zhejiang Xianju Xianle Pharmaceutical Co Ltd

indicaciones terapéuticas:

Danica 35 is indicated for the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. Danica 35 will also provide effective contraception in this patient group. It should not be used in combination with other hormonal contraceptives (see Section 4.3). Danica 35 is also indicated for the relief of symptoms of polycystic ovary syndrome.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, PVC/PVdC/Alu foil 21 tablet packed 3-off in secondary carton - 63 tablets - 36 months from date of manufacture stored at or below 25°C

Fecha de autorización:

2014-01-10